In summary, while all three vaccines induced functional CD8+ T cell responses against the OVA, Adpgk, and Irgq antigens, neoHELP generated a tumor-specific CD4+ T cell response against MHC class II-restricted neoantigen Zmiz1, and uniHELP induced a tumor-unrelated CD4+ T cell response to universal helper antigen PADRE. The gene discussed is CD4; the disease is neoplasm.